SLE
MCID: SYS001
MIFTS: 88

Systemic Lupus Erythematosus (SLE)

Categories: Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus

MalaCards integrated aliases for Systemic Lupus Erythematosus:

Name: Systemic Lupus Erythematosus 58 39 12 77 26 55 60 76 38 30 6 3 15 17
Lupus Nephritis 58 12 54 38 56 45 15 17 74
Sle 58 26 60 76
Lupus Nephritis, Susceptibility to 58 13 6
Disseminated Lupus Erythematosus 12 26 60
Lupus Erythematosus, Systemic 12 45 74
Systemic Lupus Erythematosus, Susceptibility to 58 6
Libman-Sacks Disease 26 74
Lupus Erythematosus, Systemic, Susceptibility to 41
Systemic Lupus Erythematosus Susceptibility to 58
Sle - Lupus Erythematosus, Systemic 12
Lupus Erythematosus Systemic 56
Lupus Erythematosus, Discoid 74
Lupus Erythematosus 74
Lupus Vulgaris 74
Le Syndrome 26
Lupus 26

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant

Miscellaneous:
complement deficiency (e.g. c2 and c4 null alleles) are susceptible to developing sle
association between hla class ii alleles and presence of autoantibodies
onset between ages 16-55
female to male ratio 8-13:1


HPO:

33
systemic lupus erythematosus:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Systemic Lupus Erythematosus

NINDS : 55 Lupus (also called systemic lupus erythematosus) is a disorder of the immune system. Normally, the immune system protects the body against invading infections and cancers. In lupus, the immune system is over-active and produces increased amounts of abnormal antibodies that attack the body's tissues and organs. Lupus can affect many parts of the body, including the joints, skin, kidneys, lungs, heart, nervous system, and blood vessels. The signs and symptoms of lupus differ from person to person; the disease can range from mild to life threatening. Initial symptoms of lupus may begin with a fever, vascular headaches, epilepsy, or psychoses. A striking feature of lupus is a butterfly shaped rash over the cheeks. In addition to headache, lupus can cause other neurological disorders, such as mild cognitive dysfunction, organic brain syndrome, peripheral neuropathies, sensory neuropathy, psychological problems (including personality changes, paranoia, mania, and schizophrenia), seizures, transverse myelitis, and paralysis and stroke.

MalaCards based summary : Systemic Lupus Erythematosus, also known as lupus nephritis, is related to lupus erythematosus and systemic lupus erythematosus 16, and has symptoms including seizures, pruritus and exanthema. An important gene associated with Systemic Lupus Erythematosus is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22), and among its related pathways/superpathways are Systemic lupus erythematosus and Innate Immune System. The drugs Simvastatin and belimumab have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, t cells and kidney, and related phenotypes are seizures and arthritis

Disease Ontology : 12 A lupus erythematosus that is an inflammation of connective tissue marked by skin rashes, joint pain and swelling, inflammation of the kidneys and inflammation of the tissue surrounding the heart.

Genetics Home Reference : 26 Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body. The signs and symptoms of SLE vary among affected individuals, and can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous system, and blood-forming (hematopoietic) system. SLE is one of a large group of conditions called autoimmune disorders that occur when the immune system attacks the body's own tissues and organs.

NIH Rare Diseases : 54 Lupus nephritis is a kidney disorder that is a complication of systemic lupus erythematous (SLE), commonly known as lupus. The symptoms of lupus nephritis include blood in the urine, a foamy appearance to the urine, high blood pressure, and swelling in any part of the body. This condition typically occurs in people aged 20 to 40 years. Treatment may involve medications to suppress the immune system, dialysis, or a kidney transplant. Visit our Web page on lupus for more information and resources.

OMIM : 58 Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by production of autoantibodies against nuclear, cytoplasmic, and cell surface molecules that transcend organ-specific boundaries. Tissue deposition of antibodies or immune complexes induces inflammation and subsequent injury of multiple organs and finally results in clinical manifestations of SLE, including glomerulonephritis, dermatitis, thrombosis, vasculitis, seizures, and arthritis. Evidence strongly suggests the involvement of genetic components in SLE susceptibility (summary by Oishi et al., 2008). (152700)

CDC : 3 Lupus occurs when an unknown trigger causes a person’s own immune system to attack their tissues, damaging the tissues and producing widespread inflammation. There is no known cause or cure for lupus; however, treatments are available.

UniProtKB/Swiss-Prot : 76 Systemic lupus erythematosus: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Wikipedia : 77 Systemic lupus erythematosus (SLE), also known simply as lupus, is an autoimmune disease in which the... more...

Related Diseases for Systemic Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Systemic Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1518)
# Related Disease Score Top Affiliating Genes
1 lupus erythematosus 35.8 C4A C4B CR2 CTLA4 DNASE1 FCGR2A
2 systemic lupus erythematosus 16 35.5 C4A DNASE1
3 pediatric systemic lupus erythematosus 35.1 C4A C4B STAT4
4 vitiligo-associated multiple autoimmune disease susceptibility 1 34.5 CTLA4 PDCD1 PTPN22
5 arthritis 32.9 IL10 IRF5 PTPN22 STAT4
6 rheumatoid arthritis 32.8 CTLA4 IL10 IRF5 MALAT1 PTPN22 STAT4
7 autoimmune disease 32.5 CTLA4 IL10 IRF5 PDCD1 PTPN22 STAT4
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 32.0 CTLA4 IL10 PTPN22
9 common variable immunodeficiency 31.4 BLK CR2 CTLA4 IL10
10 primary biliary cholangitis 31.0 CTLA4 IRF5
11 kawasaki disease 31.0 BLK FCGR2A IL10
12 behcet syndrome 30.9 C4A CTLA4 IL10 STAT4
13 systemic lupus erythematosus 1 12.8
14 systemic lupus erythematosus 10 12.8
15 systemic lupus erythematosus 2 12.8
16 systemic lupus erythematosus 9 12.8
17 systemic lupus erythematosus 11 12.8
18 systemic lupus erythematosus 6 12.7
19 systemic lupus erythematosus 3 12.6
20 systemic lupus erythematosus 4 12.6
21 systemic lupus erythematosus 5 12.6
22 systemic lupus erythematosus 7 12.6
23 systemic lupus erythematosus 12 12.6
24 neonatal systemic lupus erythematosus 12.5
25 systemic lupus erythematosus with hemolytic anemia 1 12.5
26 systemic lupus erythematosus with nephritis 1 12.4
27 systemic lupus erythematosus with nephritis 2 12.4
28 systemic lupus erythematosus with nephritis 3 12.4
29 systemic lupus erythematosus 8 12.4
30 systemic lupus erythematosus 13 12.4
31 systemic lupus erythematosus 14 12.4
32 systemic lupus erythematosus 15 12.4
33 neonatal lupus erythematosus 12.3
34 familial chilblain lupus 12.1
35 hypertrophic or verrucous lupus erythematosus 12.1
36 discoid lupus erythematosus of eyelid 11.9
37 c1q deficiency 11.9
38 mixed connective tissue disease 11.8
39 antiphospholipid syndrome, familial 11.8
40 sjogren syndrome 11.7
41 drug-induced lupus erythematosus 11.7
42 st. louis encephalitis 11.6
43 macrophage activation syndrome 11.6
44 pure red-cell aplasia 11.6
45 cutaneous lupus erythematosus 11.6
46 anemia, autoimmune hemolytic 11.6
47 hypogonadotropic hypogonadism 11.6
48 complement component 2 deficiency 11.6
49 epidermolysis bullosa acquisita 11.6
50 renal tubular acidosis, distal 11.6

Comorbidity relations with Systemic Lupus Erythematosus via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Chronic Kidney Failure
Chronic Myocardial Ischemia Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypersensitivity Vasculitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Mitral Valve Disease Neutropenia
Osteoporosis Postinflammatory Pulmonary Fibrosis
Raynaud Phenomenon Rheumatoid Arthritis
Sjogren Syndrome Systemic Scleroderma

Graphical network of the top 20 diseases related to Systemic Lupus Erythematosus:



Diseases related to Systemic Lupus Erythematosus

Symptoms & Phenotypes for Systemic Lupus Erythematosus

Human phenotypes related to Systemic Lupus Erythematosus:

33 (show all 14)
# Description HPO Frequency HPO Source Accession
1 seizures 33 HP:0001250
2 arthritis 33 HP:0001369
3 hemolytic anemia 33 HP:0001878
4 thrombocytopenia 33 HP:0001873
5 psychosis 33 HP:0000709
6 pericarditis 33 HP:0001701
7 cutaneous photosensitivity 33 HP:0000992
8 leukopenia 33 HP:0001882
9 pleuritis 33 HP:0002102
10 systemic lupus erythematosus 33 HP:0002725
11 antinuclear antibody positivity 33 HP:0003493
12 nephritis 33 HP:0000123
13 antiphospholipid antibody positivity 33 HP:0003613
14 malar rash 33 HP:0025300

Symptoms via clinical synopsis from OMIM:

58
Neurologic Central Nervous System:
seizures
psychosis

Hematology:
hemolytic anemia
thrombocytopenia
leukopenia

Respiratory Lung:
pleuritis

Genitourinary Kidneys:
nephritis

Laboratory Abnormalities:
antiphospholipid antibody
anti dsdna antibody
serum antinuclear antibody

Skeletal Limbs:
arthritis

Cardiovascular Heart:
pericarditis

Immunology:
systemic lupus erythematosus

Skin Nails Hair Skin:
photosensitivity
erythematous malar rash
discoid rash

Clinical features from OMIM:

152700

UMLS symptoms related to Systemic Lupus Erythematosus:


seizures, pruritus, exanthema, heliotrope rash, lupus-like rash

MGI Mouse Phenotypes related to Systemic Lupus Erythematosus:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 BLK C4B CR2 CTLA4 DNASE1 ENG
2 homeostasis/metabolism MP:0005376 10.21 C4B CR2 CTLA4 DNASE1 ENG FCGR2B
3 immune system MP:0005387 10.2 BLK C4B CR2 CTLA4 DNASE1 FCGR2A
4 cardiovascular system MP:0005385 10.18 C4B CTLA4 ENG FCGR2B IL10 PDCD1
5 endocrine/exocrine gland MP:0005379 10.09 BLK CTLA4 FCGR2B IL10 PDCD1 PTPN22
6 digestive/alimentary MP:0005381 10.06 C4B CTLA4 ENG FCGR2B IL10 PTPN22
7 mortality/aging MP:0010768 9.97 C4B CR2 CTLA4 DNASE1 ENG FCGR2A
8 liver/biliary system MP:0005370 9.86 C4B CTLA4 FCGR2B IL10 PDCD1 PTPN22
9 renal/urinary system MP:0005367 9.56 C4B CR2 DNASE1 FCGR2B PDCD1 PTPN22
10 respiratory system MP:0005388 9.23 CTLA4 ENG FCGR2B IL10 PDCD1 PTPN22

Drugs & Therapeutics for Systemic Lupus Erythematosus

Drugs for Systemic Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 426)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 356547-88-1 5957 10451420
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
4
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 118-42-3 3652
5
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
6
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
7
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 446-86-6 2265
8
Atorvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1 134523-00-5 60823
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
10
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
12
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
15
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
16
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
17
Pioglitazone Approved, Investigational Phase 4,Phase 1,Phase 2 111025-46-8 4829
18
Metformin Approved Phase 4 657-24-9 14219 4091
19
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 50-78-2 2244
20
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
21
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
22
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
23
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 143 6006
24
Sulfamethoxazole Approved Phase 4 723-46-6 5329
25
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
26
Lifitegrast Approved Phase 4 1025967-78-5
27
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
28
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
29
Lenalidomide Approved Phase 4 191732-72-6 216326
30
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
31
Adenosine Approved, Investigational Phase 4 58-61-7 60961
32
Mercaptopurine Approved Phase 4,Phase 2 50-44-2 667490
33
Thioguanine Approved Phase 4 154-42-7 2723601
34
4-Aminopyridine Approved Phase 4 504-24-5 1727
35
Sirolimus Approved, Investigational Phase 4,Phase 2 53123-88-9 46835353 5284616 6436030
36
Everolimus Approved Phase 4,Phase 2 159351-69-6 70789204 6442177
37
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
38
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 124-94-7 31307
39
Bortezomib Approved, Investigational Phase 4,Phase 2 179324-69-7 387447 93860
40
Angiotensin II Approved, Investigational Phase 4,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
41
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
42
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 7440-70-2 271
43
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 5280453 134070
44
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
45
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 1406-16-2
46
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
48
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
49 Adrenocorticotropic Hormone Phase 4,Phase 2
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 734)
# Name Status NCT ID Phase Drugs
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
2 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Unknown status NCT01753401 Phase 4 Acthar;Placebo for Acthar
3 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
6 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
7 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus Completed NCT01322308 Phase 4 pioglitazone;placebo
8 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
9 The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS Completed NCT00413361 Phase 4 versus hydroxychloroquine
10 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
11 The Effect of Metformin on Reducing Lupus Flares Active, not recruiting NCT02741960 Phase 4 metformin;placebo
12 Acthar SLE (Systemic Lupus Erythematosus) Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
13 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
14 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
15 Levothyroxine in Pregnant SLE Patients Withdrawn NCT01276782 Phase 4 Levothyroxine
16 A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Participants With Active Systemic Lupus Erythematosus (SLE) Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
17 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
18 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
19 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
20 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
21 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
22 Safety and Immunogenicity of a Zoster Vaccine in SLE Active, not recruiting NCT02477150 Phase 4
23 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
24 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
25 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
26 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
27 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
28 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
29 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
30 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
31 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
32 A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE Active, not recruiting NCT03098823 Phase 4 RAYOS;Prednisone
33 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
34 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Withdrawn NCT01926054 Phase 4 Acthar gel
35 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
36 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
37 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
38 Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Recruiting NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
39 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence Recruiting NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
40 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
41 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
42 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
43 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Active, not recruiting NCT03762824 Phase 4
44 Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
45 Pentoxifylline in Lupus Nephritis Not yet recruiting NCT03859570 Phase 4 Pentoxifylline;Placebos
46 Trial of Belimumab in Early Lupus Not yet recruiting NCT03543839 Phase 4
47 Thiopurine Induced Pancreatitis in IBD Patients Withdrawn NCT02281799 Phase 4 Azathioprine
48 Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. Recruiting NCT02849782 Phase 4 Fampridine
49 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
50 Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis Recruiting NCT02630628 Phase 4 Tacrolimus;Mycophenolate mofetil

Search NIH Clinical Center for Systemic Lupus Erythematosus

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Systemic Lupus Erythematosus cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lupus nephritis

Genetic Tests for Systemic Lupus Erythematosus

Genetic tests related to Systemic Lupus Erythematosus:

# Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus 30 CTLA4 DNASE1 FCGR2A FCGR2B PTPN22 TREX1

Anatomical Context for Systemic Lupus Erythematosus

MalaCards organs/tissues related to Systemic Lupus Erythematosus:

42
T Cells, Kidney, B Cells, Skin, Endothelial, Neutrophil, Thyroid
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Systemic Lupus Erythematosus:
# Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Systemic Lupus Erythematosus

Articles related to Systemic Lupus Erythematosus:

(show top 50) (show all 14091)
# Title Authors Year
1
Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus. ( 30408840 )
2019
2
An overlapping case of Bickerstaff brainstem encephalitis and acute motor axonal neuropathy variant of Guillain-Barré syndrome associated with systemic lupus erythematosus. ( 30444497 )
2019
3
Acute Myocardial Infarction Outcomes in Systemic Lupus Erythematosus (from the Nationwide Inpatient Sample). ( 30424870 )
2019
4
Acute pancreatitis in childhood-onset systemic lupus erythematosus: Case report. ( 31063317 )
2019
5
Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome. ( 30858846 )
2019
6
Interleukin-17/Interleukin-21 and Interferon-g producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. ( 30872365 )
2019
7
Altered Th17/Treg Ratio in Peripheral Blood of Systemic Lupus Erythematosus but Not Primary Antiphospholipid Syndrome. ( 30894863 )
2019
8
The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. ( 29669399 )
2019
9
Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. ( 29294596 )
2019
10
Psychoanalytic psychotherapy improves quality of life, depression, anxiety and coping in patients with systemic lupus erythematosus: a controlled randomized clinical trial. ( 30670099 )
2019
11
Infectious Aortitis with Abdominal Aortic Aneurysm in a 47-Year-Old Female with Systemic Lupus Erythematosus. ( 31089427 )
2019
12
Aortic aneurysm and dissection in systemic lupus erythematosus. ( 30324280 )
2019
13
Development and Validation of a microRNA Panel to Differentiate between Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus and Controls. ( 31092710 )
2019
14
T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. ( 31101603 )
2019
15
Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis. ( 31063541 )
2019
16
Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. ( 31005902 )
2019
17
Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. ( 30987474 )
2019
18
Association between tumor necrosis factor polymorphisms and rheumatoid arthritis as well as systemic lupus erythematosus: a meta-analysis. ( 30916218 )
2019
19
C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. ( 30859373 )
2019
20
Genetic variants differentially associated with rheumatoid arthritis and systemic lupus erythematosus reveal the disease-specific biology. ( 30804378 )
2019
21
Endothelial activation and injury by microparticles in patients with systemic lupus erythematosus and rheumatoid arthritis. ( 30674349 )
2019
22
Insulin resistance vary across connective tissue diseases patients: comparison between rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. ( 30652676 )
2019
23
Regulatory T Cells and Their Association with Serum Markers and Symptoms in Systemic Lupus Erythematosus and Rheumatoid Arthritis. ( 30325682 )
2019
24
An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis. ( 30568120 )
2019
25
Systemic lupus erythematosus is a risk factor for atrial fibrillation: a nation-wide, population-based study. ( 30943134 )
2019
26
IL-17A haplotype confers susceptibility to systemic lupus erythematosus but not to rheumatoid arthritis in Mexican patients. ( 30398030 )
2019
27
Mother-child histocompatibility and risk of rheumatoid arthritis and systemic lupus erythematosus among mothers. ( 30635658 )
2019
28
Correction: Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models. ( 30699190 )
2019
29
Caught in a Trap? Proteomic Analysis of Neutrophil Extracellular Traps in Rheumatoid Arthritis and Systemic Lupus Erythematosus. ( 30915077 )
2019
30
Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus. ( 30940467 )
2019
31
A case of systemic lupus erythematosus with C1q deficiency, increased serum interferon-α levels and high serum interferogenic activity. ( 30608615 )
2019
32
A unique clinical and histologic presentation of catastrophic systemic calciphylaxis in a nonuremic patient with systemic lupus erythematosus. ( 30854415 )
2019
33
Suppurative Cervical Adenitis Due to Streptococcus pneumoniae Infection in Systemic Lupus Erythematosus. ( 30998569 )
2019
34
Paraneoplastic systemic lupus erythematosus associated with colorectal cancer. ( 30800327 )
2019
35
Bilateral Orbital Compartment Syndrome Preceding Cerebellar Herniation in Neuropsychiatric Systemic Lupus Erythematosus. ( 30985493 )
2019
36
Critical limb ischemia in a patient with systemic lupus erythematosus: a case report. ( 31018871 )
2019
37
Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus. ( 30984372 )
2019
38
A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. ( 31025748 )
2019
39
Cutaneous lupus erythematosus patients with a negative antinuclear antibody meeting the American College of Rheumatology and/or Systemic Lupus International Collaborating Clinics criteria for systemic lupus erythematosus. ( 31058462 )
2019
40
Recurrent Abdominal Pain in Systemic Lupus Erythematosus: Concurrent Lupus Enteritis and Lupus Cystitis. ( 30710539 )
2019
41
The clinical features and mortality risk factors of cytomegalovirus infection in patients with systemic lupus erythematosus. ( 30598425 )
2019
42
Cytomegalovirus infection in Systemic Lupus Erythematosus: report of four cases challenging the management of the disease, and literature review. ( 30674220 )
2019
43
Relationships among organ damage, social support, and depression in African American women with systemic lupus erythematosus. ( 30482093 )
2019
44
The contributions of socioeconomic status, perceived stress, and depression to disability in adults with systemic lupus erythematosus. ( 30776317 )
2019
45
Depression and its related parameters increased the production of autoantibodies against 16α-hydroxyestrone-albumin complex in systemic lupus erythematosus. ( 30925322 )
2019
46
Roseomonas mucosa infective endocarditis in patient with systemic lupus erythematosus: case report and review of literature. ( 30755159 )
2019
47
Libman-Sacks Endocarditis in a Puerpera With Systemic Lupus Erythematosus. ( 30266614 )
2019
48
Tonic Seizure as a Different Seizure Type Presented in Autoimmune Epilepsy Caused by Systemic Lupus Erythematosus. ( 30741775 )
2019
49
Systemic Lupus Erythematosus with Familial Mediterranean Fever: Case Report and Review of Literature. ( 31017251 )
2019
50
Ficolin-3 Deficiency Is Associated with Disease and an Increased Risk of Systemic Lupus Erythematosus. ( 31044336 )
2019

Variations for Systemic Lupus Erythematosus

UniProtKB/Swiss-Prot genetic disease variations for Systemic Lupus Erythematosus:

76
# Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601
2 TREX1 p.Arg114His VAR_028319 rs72556554
3 TREX1 p.Ala158Val VAR_037949 rs762011967
4 TREX1 p.Gly227Ser VAR_037950 rs113107733
5 TREX1 p.Arg240Ser VAR_037951 rs72556555
6 TREX1 p.Ala247Pro VAR_037952 rs112741962
7 TREX1 p.Pro290Leu VAR_037954 rs148833270
8 TREX1 p.Tyr305Cys VAR_037955 rs370504038
9 TREX1 p.Gly306Ala VAR_037956 rs780022923
10 TREX1 p.Asp200His